Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Albendazole
Drug ID BADD_D00052
Description A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)
Indications and Usage For the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium and for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.
Marketing Status approved; vet_approved
ATC Code P02CA03
DrugBank ID DB00518
KEGG ID D00134
MeSH ID D015766
PubChem ID 2082
TTD Drug ID D00KVO
NDC Product Code 49452-0003; 51927-1763; 52286-0001; 63629-1221; 64896-693; 60592-002; 42799-110; 43598-452; 69539-151; 52286-5500; 42291-093; 69097-237; 69766-026; 0115-1701; 53104-7736; 31722-935; 51407-258; 63629-9278; 72205-051; 0591-2712; 51927-0068; 72643-008; 86055-0004; 73309-129; 70710-1021; 70771-1103; 78482-110
UNII F4216019LN
Synonyms Albendazole | Lurdex | Bilutac | Metiazol | Andazol | Albenza | Zentel | Albendoral | Albendazole Monohydrochloride | Monohydrochloride, Albendazole | Bendapar | Digezanol | Disthelm | Mediamix V Disthelm | Endoplus | Eskazole | Gascop | SK&F-62979 | SK&F 62979 | SK&F62979 | SKF-62979 | SKF 62979 | SKF62979 | Valbazen
Chemical Information
Molecular Formula C12H15N3O2S
CAS Registry Number 54965-21-8
SMILES CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urethral disorder20.07.01.002---
Urinary tract disorder20.08.01.001---
Urticaria10.01.06.001; 23.04.02.001--
Vertigo04.04.01.003; 17.02.12.0020.003381%
Vision blurred06.02.06.007; 17.17.01.0100.003381%
Vomiting07.01.07.0030.012679%
Lymphatic disorder01.09.01.003---
Hepatic enzyme increased13.03.04.028---
Haematotoxicity01.05.01.007; 12.03.01.0250.001691%-
Meningeal disorder17.02.10.003---
Abnormal behaviour19.01.01.0010.002536%-
Decreased appetite08.01.09.028; 14.03.01.0050.011834%
Blood disorder01.05.01.004---
Hepatobiliary disease09.01.08.003---
Bone marrow failure01.03.03.0050.001691%
Low birth weight baby18.04.02.0030.001691%-
Skin mass23.07.04.0140.001691%-
Acute kidney injury20.01.03.0160.001691%
Drug-induced liver injury09.01.07.023; 12.03.01.0440.009298%-
Faeces pale07.01.03.0050.001691%-
Normal newborn18.08.06.0010.008622%-
Drug ineffective for unapproved indication08.06.01.038; 12.09.02.0020.005410%-
Gait inability08.01.02.011; 17.02.05.0690.007607%-
Superficial inflammatory dermatosis23.03.04.0510.002536%-
The 4th Page    First    Pre   4    Total 4 Pages